Source: Wall Street Journal

As a new crown virus is popular, the geopolitical tension relationship is upgraded, and as China approaches the development of coronary virus vaccines, senior officials and pharmaceutical vendors of Chinese government have begun to promise that China will give priority to the strategic country to supply vaccines.In order to consolidate your position in the world.

The Ministry of Foreign Affairs of China has promised to prioritize the Chinese vaccine in the Philippines. At the same time, China Private Enterprise Kexing Holdings Biotechnology Co., Ltd. has agreed to cooperate with Brazil and Indonesia to produce hundreds of millions of candidate vaccines for local use.

Pakistan, one of the closest allies in developing countries in developing countries, reached an agreement with China Pharmaceutical Group Co., Ltd. (referred to as Sinopharm Group). Sinopharm Group will conduct clinical trials locally, and Pakistan will receive about one -five -fifth of the country's country.Vaccine used for population.The total population of Pakistan is 220 million.

In addition, if the Russian health department is approved, Russia may produce a vaccine developed by the Chinese military and China Kangxino Biological Corporation.

According to data from the World Health Organization, in more than 20 candidate vaccines in more than 20 clinical trials in the world, six types of human test stages that have entered the last human body, three of which were developed by Chinese state -owned and private pharmaceutical companies.The other three types of candidate vaccines in the later trial stage were developed by the United States, Britain and German companies.

Earlier, the Chinese government donated masks and medical supplies to some countries earlier this year.The Chinese government has been criticized by the United States and other countries because they did not take the new crown epidemic in a faster action.Last year, the new crown epidemic broke out in Wuhan, central China.

Global health experts predict that in the case of strong global demand, China, Russia, and other countries will try to turn any effective vaccine into diplomatic tools.

Thomas J.Bollyky, the global health leader of the Foreign Relations Association, said that the supply of vaccines is more limited compared to masks.He said: It cannot be compared at all.This is why vaccine nationalism begins to look up.

Although Russia claimed to have developed the world's first new crown vaccine last week, this statement has been questioned at home and abroad at home and abroad, worrying about whether its development operations have complied with regulatory standards.WHO has stated that it will evaluate the Russian vaccine.Even so, Russia said that 20 countries including Brazil, Indonesia and the UAE have put forward vaccine supply requirements.

Petrovax, a Russian private company, is helping to test a vaccine developed by Kangshino.Petrovax said it will produce the vaccine in the Moscow region and sell it in the country and the former Soviet Union.

The Trump administration has not explained how fast the United States can supply its own vaccine.Alex Azar, Minister of Health and Public Services, said last week that the United States will share vaccines with other countries only after the demand of its country is met.The United States is the country with the worst affected by the new crown epidemic.

Under the condition that the local epidemic is basically eliminated, China may have greater flexibility in sharing vaccines with other countries.Another reason why China sharing vaccines with other countries may be that due to the lack of new crown infection cases, it is difficult for China to conduct effective clinical trials in China.

China has become one of the world's largest vaccine producers. It produces hundreds of millions of vaccines each year. Chinese companies have been competing for production capacity while developing vaccines.

Chinese pharmaceutical companies leading in vaccines have their own production facilities, and state -owned enterprises China Biotechnology Co., Ltd. can produce 200 million doses of vaccines a year.

However, the Chinese leadership will find a subtle balance between the 1.4 billion vaccine vaccination and the possible vaccine abroad.

The Chinese government has not disclosed the details of many agreements reached with other countries.However, China's official statement hinted that China seems to blur the boundary of humanitarian and foreign policy goals. Its foreign policy goals include giving other countries in China ’s territorial claims in China.

For some countries, the vaccine developed by Chinese pharmaceutical vendors may affect the relationship with the United States, but it will help deepen diplomatic relations with China.Earlier this month, Malaysian Foreign Minister talked with Chinese Foreign Minister Wang Yi and US Secretary of State Pompeo, respectively to exchange ways to further carry out vaccine cooperation.

Neither China and the United States have promised to help Malaysia prioritize the vaccine, but in the case of tight situations in the South China Sea, China and the United States are seeking to strengthen their relationships with the Malaysian government.The United States is trying to further prevent China's territorial claims on controversial waters.

Earlier, the Philippine President Duterte had directly requested Chinese President Xi Jinping to help the country to obtain a new crown vaccine. After that, a spokesman for the Chinese Ministry of Foreign Affairs said in July that China is willing to give priority to the Philippine needs in vaccine.The Philippines also has territorial claims in the South China Sea.

In view of the fact that vaccine problems are related, the Chinese government may participate in key discussions on the sharing vaccine with state -owned pharmaceuticals and Chinese private pharmaceutical companies and foreign entities.

John J. Donneelly, the head of the California Consulting Agency Vaccinology Consulting LLC, said: If the vaccine does not work, there are safety issues, or related companies cannot supply it in accordance with their commitments, it may be embarrassing.

Countries may take a few months to use Chinese vaccines, because candidate vaccines are still undergoing clinical trials, and some may be proven to be unsuccessful.

The Ministry of Foreign Affairs, the Ministry of Science and Technology, and the General Administration of Foreign Affairs did not respond to the request of comment.

So far, vaccine procurement is basically commercialized, and wealthy countries such as the United States have placed billions of dollars in orders.The U.S. government has signed contracts to purchase hundreds of millions of vaccines from Astraikon in the United Kingdom, Moderna, and German companies Biontech SE.Biontech is working with Pfizer.The European Union and British governments are also committed to buying vaccines from these pharmacies.

Poor countries are facing the remaining danger.Global health experts said these countries may use those vaccines that have not proved completely safe and effective in regular clinical trials.

China may eventually help some of these countries.China has sought to play a greater role in helping develop countries to control diseases. In 2017, it launched a Health Silk Road and opened up new space for cooperation for its Belt and Road global infrastructure projects.

In Bangladesh, China Kochi has collaborated with the International Diagnosis Disease Research Center, which is headquartered in Daka, which is helping the company to obtain the final approval to start recruiting test volunteers.

According to the Chinese official media Xinhua News Agency, in other parts of Asia, Koxing has reached an agreement with the Indonesian State -owned Pharmaceutical Holding Company PT BIO FARMA to produce as many as 250 million vaccines for the Indonesian public each year.At the time of this transaction, Koxing was conducting clinical trials in the country. At the same time, Beijing was promoting the benefits of China's continuous expansion of infrastructure construction in Asia.

Brazil may be one of the first batch of Chinese vaccines. The exchange conditions are to test the vaccine of Kexing in Brazil.Dimas Covas, the director of Instituto Butantan supported by the Brazilian government, said that Kexing promised to sell at least 6,000 doses of vaccines to the institute in the next few months, and the institute would establish its own production plant.COVAS added that neither government two governments participated in the agreement.